Wuhan General Group Inc (WUHN)

[creakyhottie]

This could be dragging down whole sector. From Benzinga:
Investors have not reacted favorably to phase 2b results of COMPASS Pathways' (CMPS -22.1%) psilocybin treatment for treatment-resistant depression, bringing shares down.

Top-line data showed that based on the Montgomery-Asberg Depression Rating Scale (MADRS), those who received 25mg of the psilocybin treatment, COMP360, showed a -6.6 difference vs. the comparator group at week 3.

The study examined a single dose of COMP360 in 233 patients at either 10mg or 25mg.
COMPASS is beginning a phase 2 trial of COMP360 for post-traumatic stress disorder.
MindMed (MNMD -9.9%), which is also developing psychedelic therapies, is also down.